Windlab, Infigen, Tilt, and now Genex. I was a holder of all four, and have been disappointed every time.
Revenues for the assets from Windlab, Infigen, and Tilt have been huge over the past few years after acquisition. ASX investors lose out again. I’m sure it will be the same for Genex shareholders in retrospect.